Patents Assigned to MACHAVERT PHARMACEUTICALS LLC
  • PHOSPHOLIPID COMPOSITIONS
    Publication number: 20220409641
    Abstract: Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.
    Type: Application
    Filed: August 22, 2022
    Publication date: December 29, 2022
    Applicant: MACHAVERT PHARMACEUTICALS LLC
    Inventors: Jakub D. STASZAK-JIRKOVSKY, Lukas KOBR, Gregory MIKNIS, Colleen HUDSON, Luca MONFREGOLA, Pavel JIRKOVSKY, Zboncáková MILADA, Jason DUEX, Pitchaimani KANDASAMY
  • Phospholipid compositions
    Patent number: 11433085
    Abstract: Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: September 6, 2022
    Assignee: MACHAVERT PHARMACEUTICALS, LLC
    Inventors: Jakub Staszak-Jirkovsky, Lukas Kobr, Gregory Miknis, Colleen Hudson, Luca Monfregola, Pavel Jirkovsky, Zbon{hacek over (c)}áková Milada, Jason Duex, Pitchaimani Kandasamy
  • Phospholipid compositions
    Patent number: 10493086
    Abstract: Compositions involving a modified egg yolk extract for use as an effective anti-cancer agent are described. The modified egg yolk extract involves specific fractions of phosphatidylcholines and sphingomyelins modified and produced from a chemical synthesis applied to the extract that produce a beneficial effect on the inhibition of cancerous cell growth. Methods of administering these compositions are also described.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: December 3, 2019
    Assignee: MACHAVERT PHARMACEUTICALS LLC
    Inventors: Jakub Staszak-Jirkovsky, Lukas Kobr, Gregory F. Miknis, Colleen Hudson, Luca Monfregola, Pavel Jirkovsky, Zbon{hacek over (c)}áková Milada, Jason Duex, Pitchaimani Kandasamy